Invention Grant
- Patent Title: Muteins of fibroblast growth factor 21
- Patent Title (中): 成纤维细胞生长因子21的突变蛋白
-
Application No.: US11718636Application Date: 2005-12-07
-
Publication No.: US07655627B2Publication Date: 2010-02-02
- Inventor: Christopher Carl Frye , Lihua Huang , Radmila Micanovic
- Applicant: Christopher Carl Frye , Lihua Huang , Radmila Micanovic
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Lynn D. Apelgren
- International Application: PCT/US2005/044116 WO 20051207
- International Announcement: WO2006/065582 WO 20060622
- Main IPC: C07K14/50
- IPC: C07K14/50 ; A61K38/18
Abstract:
The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.
Public/Granted literature
- US20070293430A1 Muteins of Fibroblast Growth Factor 21 Public/Granted day:2007-12-20
Information query
